JP2017527613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527613A5 JP2017527613A5 JP2017529600A JP2017529600A JP2017527613A5 JP 2017527613 A5 JP2017527613 A5 JP 2017527613A5 JP 2017529600 A JP2017529600 A JP 2017529600A JP 2017529600 A JP2017529600 A JP 2017529600A JP 2017527613 A5 JP2017527613 A5 JP 2017527613A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- composition
- pro140
- hiv
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 7
- 238000009097 single-agent therapy Methods 0.000 claims description 5
- 230000009265 virologic response Effects 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 6
- 230000000798 anti-retroviral effect Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039620P | 2014-08-20 | 2014-08-20 | |
| US62/039,620 | 2014-08-20 | ||
| US201562192941P | 2015-07-15 | 2015-07-15 | |
| US62/192,941 | 2015-07-15 | ||
| PCT/US2015/046160 WO2016029049A1 (en) | 2014-08-20 | 2015-08-20 | Hiv antibody therapy as treatment substitute |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155978A Division JP7035143B2 (ja) | 2014-08-20 | 2020-09-17 | 代替処置としてのｈｉｖ抗体療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527613A JP2017527613A (ja) | 2017-09-21 |
| JP2017527613A5 true JP2017527613A5 (enExample) | 2020-05-14 |
| JP6767367B2 JP6767367B2 (ja) | 2020-10-14 |
Family
ID=55351264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529600A Expired - Fee Related JP6767367B2 (ja) | 2014-08-20 | 2015-08-20 | 代替処置としてのｈｉｖ抗体療法 |
| JP2020155978A Expired - Fee Related JP7035143B2 (ja) | 2014-08-20 | 2020-09-17 | 代替処置としてのｈｉｖ抗体療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155978A Expired - Fee Related JP7035143B2 (ja) | 2014-08-20 | 2020-09-17 | 代替処置としてのｈｉｖ抗体療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10562969B2 (enExample) |
| EP (2) | EP3904390A1 (enExample) |
| JP (2) | JP6767367B2 (enExample) |
| KR (1) | KR20170042706A (enExample) |
| CN (1) | CN106661113A (enExample) |
| AU (2) | AU2015305401A1 (enExample) |
| BR (1) | BR112017003252A2 (enExample) |
| CA (1) | CA2957817A1 (enExample) |
| ES (1) | ES2880950T3 (enExample) |
| MX (1) | MX2017002093A (enExample) |
| WO (1) | WO2016029049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016210130A1 (en) | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| CA3089848A1 (en) * | 2017-09-18 | 2019-03-21 | Cytodyn Inc. | Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy |
| WO2024008177A1 (en) * | 2022-07-08 | 2024-01-11 | Nanjing Curegene Technology Co., Ltd. | Engineered cells and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| CN1805740A (zh) | 2003-05-16 | 2006-07-19 | 马里兰大学生物技术研究所 | 下调ccr5表达的组合物及其应用方法 |
| CN101495145A (zh) * | 2005-07-22 | 2009-07-29 | 原基因药物有限公司 | 用于减少受hiv-1感染的患者中病毒负荷的方法 |
| WO2008134076A1 (en) * | 2007-04-30 | 2008-11-06 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| US10500274B2 (en) * | 2008-04-30 | 2019-12-10 | Cytodyn Inc. | Methods for reducing viral load in HIV-1 infected patients |
| RU2626512C2 (ru) * | 2010-03-01 | 2017-07-28 | Цитодин, Инк. | Концентрированные белковые фармацевтические составы и их применение |
-
2015
- 2015-08-20 CA CA2957817A patent/CA2957817A1/en not_active Abandoned
- 2015-08-20 BR BR112017003252A patent/BR112017003252A2/pt not_active Application Discontinuation
- 2015-08-20 CN CN201580044550.6A patent/CN106661113A/zh active Pending
- 2015-08-20 WO PCT/US2015/046160 patent/WO2016029049A1/en not_active Ceased
- 2015-08-20 EP EP21166771.2A patent/EP3904390A1/en not_active Withdrawn
- 2015-08-20 US US15/504,928 patent/US10562969B2/en not_active Expired - Fee Related
- 2015-08-20 JP JP2017529600A patent/JP6767367B2/ja not_active Expired - Fee Related
- 2015-08-20 KR KR1020177007086A patent/KR20170042706A/ko not_active Ceased
- 2015-08-20 ES ES15832985T patent/ES2880950T3/es active Active
- 2015-08-20 MX MX2017002093A patent/MX2017002093A/es unknown
- 2015-08-20 AU AU2015305401A patent/AU2015305401A1/en not_active Abandoned
- 2015-08-20 EP EP15832985.4A patent/EP3183270B1/en active Active
-
2020
- 2020-01-08 US US16/737,291 patent/US20200385475A1/en not_active Abandoned
- 2020-09-17 JP JP2020155978A patent/JP7035143B2/ja not_active Expired - Fee Related
-
2021
- 2021-04-07 AU AU2021202132A patent/AU2021202132A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crowell et al. | Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial | |
| Bazinet et al. | Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial | |
| Deeks et al. | HIV infection | |
| Ndjeka et al. | Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis | |
| Gulati et al. | Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome | |
| Heathcote et al. | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B | |
| JP2017503820A5 (enExample) | ||
| Su et al. | Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study | |
| JP2017537070A5 (enExample) | ||
| JP2011126917A5 (enExample) | ||
| JP2014530226A5 (enExample) | ||
| US20230120910A1 (en) | Regimens for treating hiv infections and aids | |
| JP2017527613A5 (enExample) | ||
| Martins et al. | The prevalence of hepatitis B virus infection markers and socio-demographic risk factors in HIV-infected patients in Southern Brazil | |
| Bradfute | The discovery and development of novel treatment strategies for filoviruses | |
| Guo et al. | Antiretroviral long-term efficacy and resistance of lopinavir/ritonavir plus lamivudine in HIV-1-infected treatment-naïve patients (ALTERLL): 144-week results of a randomized, open-label, non-inferiority study from Guangdong, China | |
| Chen et al. | Grand Challenges on HIV/AIDS in China–The 5th Symposium, Yunnan 2024 | |
| Tütüncü et al. | Adherence to nucleoside/nucleotide analogue treatment in patients with chronic hepatitis B | |
| Margolis et al. | Long-term safety and efficacy of CAB and RPV as 2-drug oral maintenance therapy | |
| Psomas et al. | Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science, 21–25 July 2019, Mexico City, Mexico | |
| Gorecka et al. | Skin and mucosal manifestations of immune reconstitution inflammatory syndrome in people living with HIV: a review | |
| Wolf et al. | Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis | |
| Krastev et al. | Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study | |
| US20250205268A1 (en) | Treatment of viruses with antiviral nucleosides | |
| Zheng et al. | Initiation of Dolutegravir vs Efavirenz on Viral Suppression and Retention at 6-months: A Regression Discontinuity Design |